For example, gemcitabine/abraxane instead of FOLFIRINOX in advanced pancreatic cancer, or de-escalation of doxorubicin/ifosfamide to doxorubicin in soft-tissue sarcoma, or early de-escalation of inductive immuno-oncological combination (CTLA-4/PD-1) to PD-1 monotherapy could be considered. The gene discussed is CTLA4; the disease is soft tissue sarcoma.